Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Future Considerations When Considering Partial Thymectomy.

The Annals of thoracic surgery·2026

Same author

Less May Be Enough: Clinical Equipoise for Partial Thymectomy.

The Annals of thoracic surgery·2026

Same author

Natural History, Treatment, Survival, and Causes of Mortality in Patients With Subsolid and Ground-Glass Nodules.

Chest·2026

Same author

Evaluation of a powerless portable dialysate generator in a porcine model of continuous renal replacement therapy.

BMJ military health·2026

Same author

Comparison of Oncologic Outcomes After Partial and Total Thymectomy for Stage I Thymomas.

The Annals of thoracic surgery·2025

Same author

A Systematic Review of Heated Intrathoracic Chemotherapy for Thymic Epithelial Tumors and the First Case Report of a Robotic Approach: Could a Minimally Invasive Approach Offer a New Paradigm of Care?

Journal of clinical medicine·2025

Search research articles

Related Experiment Video

Updated: Nov 6, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Invasive thymoma - Which patients benefit from post-operative radiotherapy?

Zaid Muslim^1,2, Mirza Zain Baig^1,2, Joanna F Weber^1,2

¹Department of Thoracic Surgery, Nuvance Health System, Connecticut & New York, USA.

Asian Cardiovascular & Thoracic Annals

|May 12, 2021

Summary

Post-operative radiotherapy benefits select thymoma patients. Stage III thymoma patients receiving chemotherapy alongside radiotherapy show improved survival. Tumor size and histology are not reliable indicators for radiotherapy decisions.

Keywords:

Masaoka stage Thymoma post-operative radiotherapy thymic tumors tumor size

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Nov 6, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

Oncology
Thoracic Surgery
Radiation Oncology

Background:

Thymoma treatment decisions require careful consideration of post-operative radiotherapy.
Identifying optimal candidates for adjuvant radiotherapy is crucial for improving patient outcomes.

Purpose of the Study:

To determine which thymoma patients benefit most from post-operative radiotherapy.
To analyze prognostic factors influencing the efficacy of post-operative radiotherapy in locally advanced thymoma.

Main Methods:

Utilized the Surveillance, Epidemiology, and End Results (SEER) database for thymoma patients (Stage IIB-IV).
Compared outcomes of surgery with and without post-operative radiotherapy using propensity-matched analysis.
Evaluated clinical-pathological factors, including tumor size and World Health Organization histology.

Main Results:

No survival difference observed with post-operative radiotherapy for various World Health Organization histologies or tumor sizes.
Post-operative radiotherapy improved survival only in Stage III thymoma patients.
Concurrent chemotherapy and post-operative radiotherapy demonstrated a positive prognostic impact.

Conclusions:

Stage III thymoma patients are the primary candidates for post-operative radiotherapy.
Tumor size and histology are insufficient criteria for deciding on post-operative radiotherapy.
Masaoka-Koga staging remains a key factor in guiding post-operative radiotherapy decisions for locally advanced thymoma.